The potential of erythropoietin for conferring cardioprotection complementing reperfusion

Coronary Artery Disease

Volumn 18, Issue 7, 2007, Pages 583-585

  Binbrek, Azan S ^a   Mittal, Brajesh ^a   Rao, Kabad N S ^a   Sobel, Burton E ^b  

^a RASHID HOSPITAL   (United Arab Emirates)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

Acute myocardial infarction; Estimation of infarct size; Infarct size; Preservation of myocardium; Thrombolysis; Tissue protective effects

Indexed keywords

CREATINE KINASE; ERYTHROPOIETIN; TENECTEPLASE;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; CELL DEATH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CORONARY ARTERY BLOOD FLOW; CORONARY REPERFUSION; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; SINGLE DRUG DOSE; ST SEGMENT ELEVATION; THORAX PAIN; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANIMALS; CARDIOTONIC AGENTS; CLINICAL TRIALS AS TOPIC; DOGS; ERYTHROPOIETIN, RECOMBINANT; HEART; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 35048865334     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e3282ef4ed6     Document Type: Review

References (27)

1. Yusuf S, Hawken S, Ôunpuu S, Sans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-952.
2. Dauerman HL, Sobel BE. Pharmacoinvasive therapy in acute myocardial infarction. New York: Marcel Dekker; 2005.
3. Brines ML, Ghezzi P, Keenan S, Agnello D, deLanerolle NC, Cerami C, et al. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 2000; 97:10526-10531.
4. Gorio A, Gokmen N, Erbayraktar S, Yilmaz O, Madaschi L, Cichetti C, et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 2002; 99:9450-9455.
5. Junk AK, Mammis A, Savitz SI, Singh M, Roth S, Malhotra S, et al. Erythropoietin administration protects retinal neurons from acute ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2002; 99:10659-10664.
6. Moon C, Krawczyk M, Ahn D, Ahmet I, Paik D, Lakatta EG, et al. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc Natl Acad Sci U S A 2003; 100:11612-11617.
7. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003; 112:999-1007.
8. Fiordaliso F, Chimenti S, Staszewsky L, Bai A, Carlo E, Cuccovillo I, et al. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci U S A 2005; 101:2046-2051.
9. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, et al. Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci U S A 2003; 100:4802-4806.
10. Lipsic E, Shoemaker RG, van der Mer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia, from bench to bedside. J Am Coll Cardiol 2006; 48:2161-2167.
11. Hirata A, Minamino T, Asanuma H, Fujita M, Wakeno M, Myoishi M, et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48:176-184.
12. Schneider C, Jaquet K, Malisius R, Geidel S, Bahlmann E, Boczor S, et al. Attenuation of cardiac remodeling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J 2007; 28:499-509.
13. Ferrario M, Massa M, Rosti V, Campanelli R, Ferlini M, Marinoni B, et al. Early haemoglobin-independent increase of plasma erythropoietin levels in patients with acute myocardial infarction. Eur Heart J 2007; doi:10.1093/eurheartj/ehm065.
14. Namiuchi S, Kagaya Y, Ohta J, Shiba N, Sugi M, Oikawa M, et al. High serum erythropoietin level is associated with smaller infarct size in patients with acute myocardial infarction who undergo successful primary percutaneous coronary intervention. J Am Coll Cardiol 2005; 45:1406-1412.
15. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholtz HM. Blood transfusion in elderly patients with acute myocardial infarction. New Engl J Med 2001; 345:1230-1236.
16. Rui T, Feng Q, Lei M, Peng T, Zhang J, Xu M, et al. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia/reperfusion via induction of AP-1. Cardiovasc Res 2005; 65:719-727.
17. Van der Meer P, Lipsic E, Henning RH, Boddeus K, van der Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46:125-133.
18. Heeschen C, Aicher A, Lehmann R, Fichtlischerer S, Vasa M, Urbich C, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102:1340-1346.
19. Jiang L, Huyang Y, Hunyor S, dos Remedios CG. Cardiomyocyte apoptosis is associated with increased wall stress in chronic failing left ventricle. Eur Heart J 2003; 24:742-751.
20. Binbrek A, Rao N, Absher PM, Van de Werf F, Sobel BE. The relative rapidity of recanalization induced by recombinant tissue-type plasminogen activator (r-tPA) and TNK-tPA, assessed with enzymatic methods. Coron Artery Dis 2000; 11:429-435.
21. Binbrek AS, Rao NS, Neimane D, Hatou E, Abdulali S, Sobel BE. Comparison of rapidity of coronary recanalization in men with tenecteplase versus alteplase in acute myocardial infarction. Am J Cardiol 2004; 93:1465-1468.
22. Abendschein DR, Ellis AK, Eisenberg PR, Klocke FJ, Sobel BE, Jaffe AS. Prompt detection of coronary recanalization by analysis of rates of change of concentrations of macromolecular markers in plasma. Coron Artery Dis 1991; 2:201-212.
23. Devries SR, Sobel BE, Abendschein DR. Early detection of myocardial reperfusion by assay of plasma MM creatine kinase isoforms in dogs. Circulation 1986; 74:567-572.
24. Roberts R, Henry PD, Sobel BE. An improved basis for enzymatic estimation of infarct size. Circulation 1975; 52:743-754.
25. The medical letter on drugs and therapeutics. New Rochelle, NY: The Medical Letter. Vol 49 (Issue 1260), 7 May 2007.
26. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ. Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118:362-369.
27. Marmor A, Geltman EM, Schechtman K, Sobel BE, Roberts R. Recurrent myocardial infarction: clinical predictors and prognostic implications. Circulation 1982; 66:415-421.